Share chart Aadi Bioscience, Inc.
Extended chart
Simple chart
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Main settings
| IPO date | 2017-08-08 |
|---|---|
| ISIN | US00032Q1040 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | link |
| Change price per day: | 0% (2.02) |
|---|---|
| Change price per week: | 0% (2.02) |
| Change price per month: | 0% (2.02) |
| Change price per 3 month: | -22.01% (2.59) |
| Change price per half year: | -11.4% (2.28) |
| Change price per year: | +9.78% (1.84) |
| Change price per 3 year: | -85.48% (13.91) |
| Change price per 5 year: | +201.49% (0.67) |
| Change price per year to date: | -29.37% (2.86) |
Grade
Underestimation
| Title | Value | Grade |
|---|---|---|
| P/S | 3.28 | 5 |
| P/BV | 1.63 | 8 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
|---|---|---|
| ROA, % | -62.83 | 0 |
| ROE, % | -80.79 | 0 |
| ROIC, % | 0 | 0 |
Dividends
| Title | Value | Grade |
|---|---|---|
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
|---|---|---|
| Debt/EBITDA | -0.0129 | 10 |
| Debt/Ratio | 0.0118 | 10 |
| Debt/Equity | 0.34 | 10 |
Growth impulse
| Title | Value | Grade |
|---|---|---|
| Yield Revenue, % | 85.59 | 9 |
| Yield Ebitda, % | 2293.53 | 10 |
| Yield EPS, % | 1311.81 | 10 |
Main owners
| Institutions | Volume | Share, % |
|---|---|---|
| Avoro Capital Advisors LLC | 2 849 402 | 11.6 |
| Acuta Capital Partners LLC | 1 849 402 | 7.53 |
| Alerce Investment Management, L.P. | 1 630 830 | 6.64 |
| Blackrock Inc. | 1 081 631 | 4.41 |
| Vanguard Group Inc | 859 697 | 3.5 |
| Decheng Capital LLC | 526 329 | 2.14 |
| Decheng Capital Management III (Cayman), LLC | 526 329 | 2.14 |
| Morgan Stanley | 510 671 | 2.08 |
| Vivo Capital, LLC | 509 572 | 2.08 |
| Citadel Advisors Llc | 407 722 | 1.66 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Neil P. Desai Ph.D. | Founder & Executive Chairman | 710.35k | 1965 (60 years) |
| Dr. Loretta M. Itri F.A.C.P., M.D. | Chief Medical Officer | 617.45k | 1950 (75 years) |
| Mr. David J. Lennon Ph.D. | President, CEO & Director | 277.75k | 1971 (54 years) |
| Mr. Scott M. Giacobello CPA | CFO, Treasurer, Investor Relations & Corporate Communications | 643.23k | 1970 (55 years) |
| Mr. Stephen M. Rodin J.D. | Senior VP of Legal & General Counsel | N/A | 1976 (49 years) |
| Mr. Raymond G. Steitz | Senior VP of Human Resources & Chief Human Resources Officer | N/A | 1959 (66 years) |
| Mr. Bryan Ball | Chief Technical Operations Officer | N/A | 1970 (55 years) |
About company
Address: United States, Pacific Palisades. CA, 17383 Sunset Boulevard - Open in google maps, Open in yandex maps
Website: https://aadibio.com
Website: https://aadibio.com
